<DOC>
	<DOCNO>NCT02011828</DOCNO>
	<brief_summary>The objective study determine effect cholecalciferol treatment inflammation insulin resistance , patient hemodialysis previously treat paricalcitol . Cholecalciferol produce action sunlight cholesterol precursor skin . This compound convert calcidiol ( 25 ( OH ) D3 ) liver , whereupon calcidiol convert kidney calcitriol ( 1,25 ( OH ) 2D3 ) , active form vitamin D. However , recently show deficiency either calcidiol calcitriol associate inflammation , insulin resistance increase mortality general population . Furthermore , calcidiol calcitriol deficient , mortality risk much high deficiency either alone . A possible explanation non-renal tissue might critically depend endogenous conversion calcidiol calcitriol circulating level calcitriol . Thus , low circulating level calcidiol might associate tissue level functional calcitriol deficiency despite adequate circulating level calcitriol . Therefore , hypothesis : 1 . In non-diabetic hemodialysis ( HD ) patient treat therapeutic dos paricalcitol ( analog calcitriol ) , calcidiol deficiency associate inflammation insulin resistance 2 . In calcidiol deficient , non-diabetic HD patient inflammation treat therapeutic dos paricalcitol , cholecalciferol reverse calcidiol deficiency thereby , reduce inflammation insulin resistance . Interleulin-6 ( IL-6 ) think play central role insulin resistance down-regulating glucose transporter-4 messenger RNA . Furthermore , IL-6 level significantly negatively associate calcidiol level , therefore measure primary outcome .</brief_summary>
	<brief_title>Ergocalciferol Therapy Calcidiol Deficient , Hemodialysis Patients Therapeutic Doses Paricalcitol</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcifediol</mesh_term>
	<criteria>Nondiabetic incenter HD patient stable dos paricalcitol past three month intact parathyroid hormone ( iPTH ) therapeutic range ( 150300 pg/ml ) identify review dialysis program electronic medical record . Woman reproductive age group ( age 1855 ) , exclude woman undergone hysterectomy , oopherectomy undergo serum βHCG level selection process . If βHCG level positive patient exclude study . Inclusion criterion : Non diabetic patient HD , stable dose paricalcitol supplement least 3 month iPTH target range . Of 60 patient enrol observational component , high CRP ( &gt; 3 mg/dl ) calcidiol deficiency ( &lt; 15 ng/ml ) eligible participate interventional study . As median CRP HEMO Study 11 mg/L &gt; 80 % HD patient calcidiol deficient [ 10 ] , screen patient eligible . In year , first 12 patient meet criterion consent interventional component , randomize crossover trial cholecalciferol 50,000 IU/ week vs. match placebo conduct . Exclusion criterion : Diabetic patient , paricalcitol , enrol interventional study , hospitalize past month treat infection past month pregnancy . We conduct pregnancy test woman reproductive age group ( 1855 year ) initial screen process . We obtain serum βHCG level rule pregnancy test pay study . The result review PI . If βHCG level positive patient withdrawn study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hemodialysis , paricalcitol</keyword>
</DOC>